Monthly
US$200
Billed every month
Sign in to subscribeMetronidazole Suppositories
As of 14 November 2026, for Metronidazole Suppositories, 1 application is listed as under review at China's CDE; 2 companies have filed new generic applications in 2026; the chemical-drug catalogue lists 0 holders.
Companies, stages and changes, with each record available on this page.
Last 90 days: Accepted: 1 applicationNo longer listed under review: 1 application
Current coverage may be incomplete
Which companies are listed, and at what stages?
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.
Catalogue holders0View records ↓
Under-review filings1View records ↓
This year’s generic filers2View records ↓
NHSA approval numbers25View records ↓
API companies with A status23View records ↓
Chemical-drug catalogue
Loaded records: 0 holders; 0 in the quality-and-efficacy consistency-evaluation category, and 0 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| No matching records were found in the currently loaded source data; coverage dates are listed below. | ||||||
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
NHSA drug codes
Loaded records: 25 distinct approval numbers and 18 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| Beijing Shuang Ji Pharmaceutical Co., Ltd. romanized | 国药准字H11022305 | 0.5g | Category A | XG01AFJ070D003010100176 | NHSA |
| Guo Yao Group Gong Ye Co., Ltd. romanized | 国药准字H31020395 | 0.5g | Category A | XG01AFJ070D003010100814 | NHSA |
| Tianjin Jin Yao Pharma Co., Ltd. romanized | 国药准字H12020699 | 1g | Category A | XG01AFJ070D003010100952 | NHSA |
| Hubei Dong Xin Pharma Co., Ltd. romanized | 国药准字H42021784 | 0.5g | Category A | XG01AFJ070D003010101792 | NHSA |
| Hubei Qian Jiang Pharmaceutical Co., Ltd. romanized | 国药准字H42021261 | 0.5g | Category A | XG01AFJ070D003010101853 | NHSA |
| Ma Ying Long Pharma Group Co., Ltd. romanized | 国药准字H42020376 | 0.5g | Category A | XG01AFJ070D003010101954 | NHSA |
| Hubei Sheng Hong Yuan Pharma Technology Co., Ltd. romanized | 国药准字H42021747 | 0.5g | Category A | XG01AFJ070D003010101974 | NHSA |
| Chengdu Di Yi Pharmaceutical Co., Ltd. romanized | 国药准字H51023193 | 0.5g | Category A | XG01AFJ070D003010102080 | NHSA |
| Shanxi Shuang Yan Pharma Co., Ltd. romanized | 国药准字H14020743 | 0.5g | Category A | XG01AFJ070D003010102954 | NHSA |
| Heilongjiang Sheng Fu Dong Pharmaceutical Co., Ltd. romanized | 国药准字H23020677 | 0.5g | Category A | XG01AFJ070D003010103761 | NHSA |
| Heilongjiang Sheng Ji Ren Pharma Co., Ltd. romanized | 国药准字H20058324 | 0.5g | Category A | XG01AFJ070D003010103767 | NHSA |
| Wei Hai Hua Xin Pharma Group Co., Ltd. romanized | 国药准字H37021380 | 0.5g | Category A | XG01AFJ070D003010104217 | NHSA |
| Anhui Tian Yang Pharma Co., Ltd. romanized | 国药准字H20065914 | See source | Category A | XG01AFJ070D003010104350 | NHSA |
| Zhejiang Sha Pu Ai Si Pharma Co., Ltd. romanized | 国药准字H33022186 | 0.5g | Category A | XG01AFJ070D003010104693 | NHSA |
| Ming Shun Medical Investment (Shenzhen) Co., Ltd. romanized | 国药准字H43021486 | 0.5g | Category A | XG01AFJ070D003010104920 | NHSA |
| Heilongjiang Jia Yue Ze Biopharmaceutical Co., Ltd. romanized | 国药准字H45021412 | 0.5g | Category A | XG01AFJ070D003010105095 | NHSA |
| Name not romanized | 国药准字H53021276 | 0.5g | Category A | XG01AFJ070D003010105599 | NHSA |
| Yunnan Bai Yao Group Co., Ltd. romanized | 国药准字H53021481 | 0.5g | Category A | XG01AFJ070D003010105612 | NHSA |
| Heilongjiang Sheng Fu Dong Pharmaceutical Co., Ltd. romanized | 国药准字H23020677 | 0.5g | Category A | XG01AFJ070D003010203761 | NHSA |
| Heilongjiang Sheng Ji Ren Pharma Co., Ltd. romanized | 国药准字H20058324 | 0.5g | Category A | XG01AFJ070D003010203767 | NHSA |
| Wei Hai Hua Xin Pharma Group Co., Ltd. romanized | 国药准字H37021380 | 0.5g | Category A | XG01AFJ070D003010204217 | NHSA |
| Ming Shun Medical Investment (Shenzhen) Co., Ltd. romanized | 国药准字H43021486 | 0.5g | Category A | XG01AFJ070D003010204920 | NHSA |
| Heilongjiang Jia Yue Ze Biopharmaceutical Co., Ltd. romanized | 国药准字H45021412 | 0.5g | Category A | XG01AFJ070D003010205095 | NHSA |
| Heilongjiang Sheng Fu Dong Pharmaceutical Co., Ltd. romanized | 国药准字H23020677 | 0.5g | Category A | XG01AFJ070D003010303761 | NHSA |
| Heilongjiang Sheng Ji Ren Pharma Co., Ltd. romanized | 国药准字H20058324 | 0.5g | Category A | XG01AFJ070D003010303767 | NHSA |
| Ming Shun Medical Investment (Shenzhen) Co., Ltd. romanized | 国药准字H43021486 | 0.5g | Category A | XG01AFJ070D003010304920 | NHSA |
| Heilongjiang Jia Yue Ze Biopharmaceutical Co., Ltd. romanized | 国药准字H45021412 | 0.5g | Category A | XG01AFJ070D003010305095 | NHSA |
| Heilongjiang Jia Yue Ze Biopharmaceutical Co., Ltd. romanized | 国药准字H45021412 | 0.5g | Category A | XG01AFJ070D003010405095 | NHSA |
| Beijing Shuang Ji Pharmaceutical Co., Ltd. romanized | 国药准字H11022304 | 0.25g | Category A | XG01AFJ070D003020100176 | NHSA |
| Hubei Sheng Hong Yuan Pharma Technology Co., Ltd. romanized | 国药准字H42021747 | 0.5g | Category A | XG01AFJ070D003020101974 | NHSA |
| Chengdu Di Yi Pharmaceutical Co., Ltd. romanized | 国药准字H51023192 | 1g | Category A | XG01AFJ070D003020102080 | NHSA |
| Heilongjiang Sheng Fu Dong Pharmaceutical Co., Ltd. romanized | 国药准字H23020677 | 0.5g | Category A | XG01AFJ070D003020103761 | NHSA |
| Ming Shun Medical Investment (Shenzhen) Co., Ltd. romanized | 国药准字H43021485 | 1.0g | Category A | XG01AFJ070D003020104920 | NHSA |
| Name not romanized | 国药准字H53021275 | 1.0g | Category A | XG01AFJ070D003020105599 | NHSA |
| Yunnan Bai Yao Group Co., Ltd. romanized | 国药准字H53021482 | 1g | Category A | XG01AFJ070D003020105612 | NHSA |
| Ming Shun Medical Investment (Shenzhen) Co., Ltd. romanized | 国药准字H43021485 | 1.0g | Category A | XG01AFJ070D003020204920 | NHSA |
| Ming Shun Medical Investment (Shenzhen) Co., Ltd. romanized | 国药准字H43021485 | 1.0g | Category A | XG01AFJ070D003020304920 | NHSA |
| Heilongjiang Sheng Fu Dong Pharmaceutical Co., Ltd. romanized | 国药准字H23020677 | 0.5g | Category A | XG01AFJ070D003020403761 | NHSA |
| Ming Shun Medical Investment (Shenzhen) Co., Ltd. romanized | 国药准字H43021485 | 1.0g | Category A | XG01AFJ070D003020404920 | NHSA |
| Beijing Shuang Ji Pharmaceutical Co., Ltd. romanized | 国药准字H11021389 | 0.5g | Category A | XG01AFJ070D003030100176 | NHSA |
| Beijing Shuang Ji Pharmaceutical Co., Ltd. romanized | 国药准字H11021389 | 0.5g | Category A | XG01AFJ070D003030200176 | NHSA |
| Beijing Shuang Ji Pharmaceutical Co., Ltd. romanized | 国药准字H11021388 | 1g | Category A | XG01AFJ070D003040100176 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Current under-review applications
Loaded records: 1 filings and 1 distinct first applicants.
Supplement 1
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| Hubei Dong Xin Pharma Co., Ltd. romanized | CYHB2601150 | Supplement | 2026/06/17 | Not stated by source | CDE |
New generic filings in 2026
Loaded records: 2 filings and 2 distinct first applicants.
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| Jiangsu Yu Xing Pharmaceuticals Technology Co., Ltd. romanized | CYHL2600088 | Generic | 2026/08/19 | Not stated by source | CDE |
| Haerbin Tian Mei Pharma Co., Ltd. romanized | CYHL2600078 | Generic | 2026/07/10 | Not stated by source | CDE |
API registrations
Non-component matches: 23 companies with A status and 0 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| 甲硝唑 · No verified English name | Jinan Ming Xin Pharmaceutical Co., Ltd. romanized | Y20240000004 | A | Exact ingredient | 2025/08/01 | CDE |
| 甲硝唑 · No verified English name | Xin He Yuan Sheng Pharmaceutical Co., Ltd. romanized | Y20220000637 | A | Exact ingredient | 2026/03/03 | CDE |
| 甲硝唑 · No verified English name | AARTI DRUGS LIMITED | Y20210000013 | A | Exact ingredient | 2023/04/07 | CDE |
| 甲硝唑 · No verified English name | Guangxi Jin Xing Pharmaceutical Co., Ltd. romanized | Y20209990025 | A | Exact ingredient | 2024/10/09 | CDE |
| 甲硝唑 · No verified English name | Huang Gang Yin He A Di Pharma Co., Ltd. romanized | Y20190009773 | A | Exact ingredient | 2026/01/20 | CDE |
| 甲硝唑 · No verified English name | Hubei Sheng Hong Yuan Pharma Technology Co., Ltd. romanized | Y20190009755 | A | Exact ingredient | — | CDE |
| 甲硝唑 · No verified English name | Shanxi Tong Ji Pharma Co., Ltd. romanized | Y20190008615 | A | Exact ingredient | 2026/08/05 | CDE |
| 甲硝唑 · No verified English name | Wuhan Wu Yao Pharmaceutical Co., Ltd. romanized | Y20190008552 | A | Exact ingredient | 2025/06/12 | CDE |
| 甲硝唑 · No verified English name | Qingdao Shou He Jin Hai Pharmaceutical Co., Ltd. romanized | Y20190005405 | A | Exact ingredient | 2024/01/12 | CDE |
| 甲硝唑 · No verified English name | Jiangsu Ji Bei Er Pharma Co., Ltd. romanized | Y20190004966 | A | Exact ingredient | 2025/05/07 | CDE |
| 甲硝唑 · No verified English name | Gui Lin Nan Yao Co., Ltd. romanized | Y20190004293 | A | Exact ingredient | 2025/01/18 | CDE |
| 甲硝唑 · No verified English name | Dong Gang Shi Hong Da Pharmaceutical Co., Ltd. romanized | Y20190004198 | A | Exact ingredient | 2025/04/15 | CDE |
| 甲硝唑 · No verified English name | Guangdong Xiang Xue Pharma Co., Ltd. romanized | Y20190003967 | A | Exact ingredient | — | CDE |
| 甲硝唑 · No verified English name | Jin Zhou Jiu Tai Pharma Co., Ltd. romanized | Y20190003819 | A | Exact ingredient | 2025/05/13 | CDE |
| 甲硝唑 · No verified English name | Dan Dong Yi Chuang Pharma Co., Ltd. romanized | Y20190003816 | A | Exact ingredient | 2025/06/07 | CDE |
| 甲硝唑 · No verified English name | Wan Bang De Pharmaceutical Group Co., Ltd. romanized | Y20190003607 | A | Exact ingredient | 2024/11/02 | CDE |
| 甲硝唑 · No verified English name | Suzhou Hong Sen Pharma Co., Ltd. romanized | Y20190003215 | A | Exact ingredient | 2025/06/06 | CDE |
| 甲硝唑 · No verified English name | Yi Chang Dong Yang Guang Chang Jiang Pharma Co., Ltd. romanized | Y20190003169 | A | Exact ingredient | — | CDE |
| 甲硝唑 · No verified English name | Hebei Guang Xiang Pharmaceutical Co., Ltd. romanized | Y20190002958 | A | Exact ingredient | 2024/07/23 | CDE |
| 甲硝唑 · No verified English name | Shanxi Qian Yuan Pharmaceuticals Group Co., Ltd. romanized | Y20190002879 | A | Exact ingredient | — | CDE |
| 甲硝唑 · No verified English name | Huang Gang Sai Kang Pharma Co., Ltd. romanized | Y20190002607 | A | Exact ingredient | 2026/05/20 | CDE |
| 甲硝唑 · No verified English name | Heng Cheng Pharmaceutical Group Huai Nan Co., Ltd. romanized | Y20190002432 | A | Exact ingredient | 2025/01/14 | CDE |
| 甲硝唑 · No verified English name | Guangdong Hua Run Shun Feng Pharma Co., Ltd. romanized | Y20190001518 | A | Exact ingredient | 2024/08/15 | CDE |
| 甲硝唑 · No verified English name | Huang Gang Yin He A Di Pharma Co., Ltd. romanized | Y20170001867 | A | Exact ingredient | 2024/10/17 | CDE |
| 甲硝唑 · No verified English name | Hubei Sheng Hong Yuan Pharma Technology Co., Ltd. romanized | Y20170001945 | A | Exact ingredient | 2026/02/05 | CDE |
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
What changed recently?
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.
Trial registration does not mean an application will follow.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/14 06:40. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.
-
2026/10/29No longer listed under review
Jiangsu Yu Xing Pharmaceuticals Technology Co., Ltd. romanized
CYHL2600088
Fact date: 2026/10/29 · Site observation date: 2026/10/29
Accepted: 2026/08/19
not on the CDE under-review list in this snapshot; the review / approval outcome is to be checked
View source ↗ -
2026/08/19Accepted
Jiangsu Yu Xing Pharmaceuticals Technology Co., Ltd. romanized
CYHL2600088
Fact date: 2026/08/19 · Site observation date: 2026/10/21
View source ↗
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/14 06:44
- Chemical-drug catalogue
- Last successful update: 2026/11/14 06:40
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
- Full API register
- Last successful update: 2026/11/14 06:43
- NHSA drug codes
- Last successful update: 2026/11/05 06:45
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
- NMPA drug delivery notices
- Last successful update: 2026/11/14 18:32
First index-page publication dates: 2026-10-29 to 2026-11-13; 0 pages pending. Covers loaded notices only, not a complete historical approval database.
- Drug Clinical Trial Registry and Information Disclosure Platform
- Last successful update: 2026/11/14 08:10 · Current coverage may be incomplete
Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
Public-product searches scanned: 7/30; discovered pending details: 0. Record counts in unscanned portions remain unknown.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Follow changes to Metronidazole Suppositories
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Subscriptions
Next-day facts and deliverable timelines
- One email the next day when new facts are collected for your followed products.
- Export the complete loaded event timeline for each followed product as CSV.
- Add up to 4 additional recipients, each confirmed by email.
- Increase your follow limit from 3 to 10 products.
Quarterly
US$540
Billed every three months
US$180 per month
Sign in to subscribeYearly
US$1,920
Billed every year
US$160 per month
Sign in to subscribeNeed more than 10 followed products or more than 5 recipients? Contact us.
Separate one-time purchase
US Orange Book × China records comparison
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
Billed by Creem, our merchant of record · Terms · Refund policy